CelLBxHealth plc · LSE:CLBX
CelLBxHealth — ANGLE — H1 2020 Earnings Presentation
16 slides from CelLBxHealth's earnings presentation, Oct 29, 2020
Slide 1: Interim Results for the six months ended 30 June 2020
Interim Results for the six months ended 30 June 2020 Andrew Newland and Ian Griffiths 29 October 2020
Slide 2: Legal disclaimer
LSE AIM: AGL OTCQX: ANPCY Legal disclaimer This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The presentation slides which follow this notice and the oral presentation of whi
Slide 3: Liquid biopsy - improving patient outcomes and reducing healthcare costs
Liquid biopsy - improving patient outcomes and reducing healthcare costs Parsortix® cassette “ANGLE’s mission is to enable personalised cancer care by providing the complete picture of the patient’s cancer from a simple blood test. Product-based solution for simple, effective, affordable repeat test
Slide 4: Highlights
Highlights Leading cancer centres with original research and peer-reviewed publications using ANGLE’s Parsortix system (selection) Sustained focus on four-pronged strategy is delivering clinical studies, regulatory approval, published evidence, and partnerships • FDA submission made post-period end:
Slide 5: Financial Results for six months ended 30 June 2020
Financial Results for six months ended 30 June 2020 Six months ended 30 June 2020 2019 Statement of Comprehensive Income £’000 £’000 Comments Revenue 235 384 • Revenue down 40%; COVID-19 Cost of sales (59) (96) impact on customers Gross profit 176 288 • Gross margin 75% Operating costs (6,009) (6,44
Slide 6: FDA substantive review in process for MBC
FDA substantive review in process for MBC Seeking first ever FDA clearance for a device to harvest Four leading US cancer centres participated cancer cells from patient blood for subsequent analysis • ahead of known competition with five years of clinical • University of Texas MD Anderson Cancer Cen
Slide 7: Prospect of FDA clearance earliest Q2 CY21
Prospect of FDA clearance earliest Q2 CY21 • FDA De Novo Submission for Class II clearance in metastatic breast cancer submitted 25 September 2020 – over 15,000 samples and 400 reports and technical documents • Q-Submission process followed to de-risk process • Successful FDA administrative review a
Slide 8: Commercial pathways open up post FDA clearance
Commercial pathways open up post FDA clearance • Existing research use only (RUO) sales to leading translational researchers is expected to accelerate with Research Pharma LDTs Clinical products FDA clearance and expand with sample-to answer solutions Leveraged R&D Large scale Laboratory Product sal
Slide 9: Ovarian cancer pelvic mass triage test clinical study in progress
Ovarian cancer pelvic mass triage test clinical study in progress • 5-10% of women suffer from abnormal pelvic mass. 295,000 women diagnosed globally with ovarian cancer in 2018 • Two 200 patient studies already completed with best in class results AUC >95% accuracy achieved. Potential for high sens
Slide 10: Growing body of evidence Leveraged R&D strategy identifying new applications
Growing body of evidence Leveraged R&D strategy identifying new applications Research use pricing Instrument Cassette • Translational research market US $50 million p.a. Price1 $50,000 $100 • FDA clearance expected to help Parsortix become the CTC system of choice Cost $15,6002 $15 Margin 69% 85% •
Slide 11: Nine peer-reviewed publications 2020 year-to-date
Nine peer-reviewed publications 2020 year-to-date • Edith Cowan University in Perth, Australia treatment response in melanoma • University Medical Center Hamburg-Eppendorf, Germany in breast cancer including single cell analysis • Istituto Nazionale Tumori di Milano, Milano, Italy in renal cell carc
Slide 12: Partnership potential to enable entire industry
Partnership potential to enable entire industry Wide variety of partnerships possible due to product-based approach with: • Medtech companies to expand revenue opportunities for installed base – expand from one-off tissue biopsy to repeat liquid biopsy tests – Abbott breast cancer FISH HER2 • Pharma
Slide 13: New funding will accelerate commercialisation
New funding will accelerate commercialisation Accredited clinical laboratories being established in US and UK as accelerator and demonstrator • Pharma services and initial clinical services • Offer new tests: – epithelial, EMTing, mesenchymal CTCs and clusters – ER/PR/HER2 application – PD-L1 immuno
Slide 14: Building on a leading position in the liquid biopsy market
Building on a leading position in the liquid biopsy market Leading cancer centres with original research and peer-reviewed publications using ANGLE’s Parsortix system (selection) • Highly differentiated solution for the emerging multi US$ billion liquid biopsy market • Prospect of FDA clearance earl
Slide 15: Investment Overview
Investment Overview ANGLE’s Parsortix® system is a simple blood test for personalised cancer Large scale clinical studies in ovarian cancer significantly out-performed care, which harvests viable intact cancer cells (CTCs) for analysis existing standard of care • unique patented microfluidic approac
Slide 16: ANGLE plc contact details
ANGLE plc ANGLE Europe Ltd 10 Nugent Road Surrey Research Park Guildford GU2 7AF United Kingdom ANGLE North America Inc 1150 First Avenue, Suite 1010 Parkview Tower King of Prussia PA 19406 USA ANGLE Biosciences Inc 50 Ronson Drive, Suite 105 Toronto Ontario M9W 1B3 Canada www.angleplc.com 16